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NK cellBackground: Killer cell immunoglobin-like receptors (KIR) are the transmembrane glycoproteins on nat-
ural killer (NK) cells that regulate their functions. Studies show that immune system plays roles in neu-
rodevelopmental disorders like autism, and NK cell abnormality can be a risk factor in autism spectrum
disorders.
Aim: This study aims to investigate the role of KIR genes diversity in autism.
Methods: In order to find the relevant literature, we used PubMed, Google Scholar and other search
engines. Association of each gene was analyzed through chi-square with Yate’s correction (or Fisher’s
exact test if necessary). Software comprehensive meta-analysis was used. Both fixed and random effect
models were reported.
Results: Among fourteen genes of KIR, the risk role of KIR2DS1 and KIR3DS1 were statistically significant
based on fixed effect model. Among these two genes, KIR2DS1 needed random effect model because of its
heterogeneity. After applying random effect, its role was not significant. The funnel plot showed no pub-
lication bias for KIR3DS1, and its role was significant based on fixed effect model (P = .028; OR = 1.31).
Conclusions: Autism spectrum disorders are accompanied by KIR3DS1 which is an activating gene of KIR.
It seems that hyper-activity of NK cells results in inflammation in neuroimmune system that in turn can
be associated with autism. The legend of 3DS1 receptor is unknown, and suggested to be investigated.
This meta-analysis should be updated in future.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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1.1. Rationale
1.1.1. About autism
Autism is a neurodevelopmental disorder specified by verbal
and nonverbal communicational and social interaction dysfunc-
tions. The main cause of autism is not clear. Symptoms reveal
before the age of 3 and this disorder is more prevalent in boys. Role
of economic and social status, life style and the level of education
in parents is controversial. Autistic children may show aggression
and self-harm behaviors, abnormal responses to people, unusual
attachment to objects, resistance to changes, repetitive activities
such as flapping, jumping and also hypersensitivity in the five
senses [1–3].1.1.2. About neuroimmunology
Neuroimmune system includes structures and process like bio-
chemical and electrophysiological reactions between nervous and
immune systems that protect neurons from pathogens. This sys-
tem has selective permeable barriers such as brain blood barrier
(BBB) and cerebrospinal fluid (CSF) protecting neurons against dis-
eases and also mediating neurons inflammation and trauma.
Among all immune cells just mast cells are naturally present in
neuroimmune system, because other cells do not pass BBB. When
immune responses are needed, they’ll be able to pass BBB and be
imported in CSF. Neuroimmune system is formed by glial cells ini-
tially. For this reason, it is different from peripheral immune sys-
tem. Immune and nervous systems linked together extensively
and intricately by cytokines and neuromediators like neuropep-
tides. On the other hand immune system function affects many
biological processes that we can mention the pathogenesis of neu-
rodegenerative diseases, neurodevelopmental disorders such as
autism, and mental health disorders such as schizophrenia. More-
over brain function and development can be affected when innate
and adaptive immune responses are not regulated. It’s hope that
knowing the relation between immune and nervous systems helps
us to prevent and treat neurological diseases. Immune system role
in autism is a dynamic field of research which can be referred to
brain antibodies, serum cytokines, family history and immuno-
genetics. Proinfammatory cytokines increase like the interleukin
(IL)-1beta and interferon (IFN)-gamma produced by peripheral
mononuclear cells play role in neurodevelopmental process [4–8].1.1.3. Natural killer cells in neuroimmunology
Natural killer (NK) cells are a group of immune cells playing role
in immune response regulation, and change in their activity is
along with immune disorders [9]. These cells are known as the
main source cytokines producers, such as IFN-gamma in pathologic
and physiologic situations and they are involved in neurodevelop-
mental disorders like autism. For this reason, some studies have
been done about NK cells’ role in autism. NK cells abnormality
can be a sensitizer factor in autism spectrum disorders, and may
prepare the situation for neuroimmune reactions in important
developmental periods [10,11]. NK cells have the killer-cell
immunoglobulin-like receptors (KIR) interacting with some types
of human leukocyte antigens (HLA) [12]. Both KIR and HLA have
a variety of genes that each gene is highly polymorphic in turn.
KIR has fourteen genes; 8 of them are inhibitory (know with DL
in their names) and 6 of them are activating (known with DS in
their names). Ten of them are shown in Table 1. These genes are
inherited as haplotype pattern and then there are a lot of geno-
types in different individuals [13–16]. NK cells have two subtypes;
CD56dim and CD56bright. IL-2 induces expression of the CD57 which
is observed in matured NK cells and is differentiated form of
CD16+CD56dim NK cells. These cells have more toxic capacity and
are more sensitive to CD16 stimulation, but their response to
cytokines and proliferation have decreased. CD57 marker also
expresses in CD8+ T cells, and is related to close to death phases
and cells’ old age. In chronic immune activation, CD57 expresses
more in T cells [11,17,18].1.2. Objectives
According to the literature above, we decided to investigate the
association of each different genes of KIR with risk of autism as a
brief meta-analysis; because the place of immunology in behav-
ioral sciences is not clear.2. Methods and evidence acquisition
Present meta-analysis has been conducted based on Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA, http://www.prisma-statement.org/). We used compre-
hensive meta-analysis 2 software (Biostat, US, https://www.
meta-analysis.com/).
Table 1
Summary of the collected data from 3 populations.
Gene Torres et.al. (2012) Yate’s corrected (or Fisher
exact) P value (ED)
Guerini. F, et al.
(2014) (Italy)
Yate’s corrected (or Fisher
exact) P value (ED)
Guerini et al.
(2014) (Sardinia)
Yate’s corrected (or Fisher













2DL1 153 172 0.7402() 89.1 242.5 0.3410(+) 71.25 116.16 1(+)
2DL2 88 96 0.9203(+) 50.4 145 1() 42.75 65.34 1(+)
2DL3 144 162 0.9203() 77.4 212.5 1(+) 58.5 107.69 0.0557()
3DL1 148 174 0.0243() 82.8 235 1() 72 112.53 1(+)
2DS1 95 67 <0.0001(+) 36 97.5 1(+) 28.5 54.45 0.6021()
2DS2 90 97 0.8230(+) 63 140 0.0297(+) 39.75 64.13 1(+)
2DS3 54 46 0.1380(+) 30.6 97 1() 21.75 39.93 1()
2DS4 154 160 0.0219(+) 81 225 1(+) 72 108.9 0.2865(+)
2DS5 68 53 0.0193(+) 26.1 72.5 1(+) 24 39.93 1()
3DS1 83 65 0.0058(+) 36.9 87.5 0.4223(+) 27.75 42.35 1(+)
ED: effect direction. Positive EDs show the genes as a risk factor and negative EDs show the gene as a protecting factor.
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The present study has not ever been registered. As well, we
searched in PROSPERO (NHS, UK, https://www.crd.york.ac.uk/
PROSPERO/) in order to find other registered works. The founded
records were as following: autism = more than 100; KIR = 1; aut-
ism AND KIR = 0.2.2. Eligibility criteria
All the studies in scientific databases covering both KIR and
autism.2.3. Information sources
We used Google Scholar, Science Direct, PubMed and Web of
Science.2.4. Search
We searched for (KIR OR the complete form) AND (autism OR
ASD) in titles.2.5. Study selection
The process is shown as a flowchart in Fig. 1.2.6. Data collection process
Wewere trying to extract data of each KIR genes in both autistic
and healthy children. The summary is shown in Table 1.2.7. Data items
Data of Table 1 are based on absolute frequency of each gene.
All percentages were converted to absolute number.13 studies found 







Fig. 1. Document search an2.8. Risk of bias in individual studies
This risk has been controlled through Yate’s correction or Fish-
er’s exact test (each of them with upper P value).
2.9. Summary measures
The forest plots were designed based on two-tailed P values and
sample size of each study. The odds ratios were estimated by the
software. Since the P values were calculated with Yate’s correction
or Fisher’s exact test, the obtained odds ratios would be under-
estimated. This protocol has been previously published [19].
2.10. Synthesis of results
The pooled P value and effect size (odds ratio) of each gene were
reported based on both fixed and random effect models. No hetero-
geneity statistical test was used because of low number of
imported studies. We used funnel plots instead.
2.11. Risk of bias across studies
It was important to us that all 3 populations should be inside
the funnel. In such cases fixed effect model was valid to us, and
in genes with bias, random effect model was valid. As well, Yate’s
correction or Fisher’s exact test in turn helped this aim.
2.12. Additional analyses
For family comparison of KIR genes, Bonferroni’s correction was
adjusted to the pooled P values of the genes.
3. Results
3.1. Studies’ characteristics
This meta-analysis covered the information of 323 autistic chil-







from 2 studies 
were impoeted in 
meta-analysis
d screening flowchart.
Model Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Torres (2012) 2/190 1/469 3/267 3/844 0/000
Guerini (2014) (Italy) 1/000 0/679 1/473 0/000 1/000
Guerini (2014) (Sardinia) 0/873 0/523 1/457 0/521- 0/603
630/0201/2066/1810/1003/1dexiF
734/0877/0322/2807/0552/1modnaR
0/01 0/1 1 10 100
Favours A Favours B
Fig. 2. Forrest plot of KIR2DS1.














Funnel Plot of Standard Error by Log odds ratio
Fig. 3. Funnel plot of KIR2DS1.
Model Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Torres(2012) 1/738 1/171 2/581 2/741 0/006
Guerini(2014)(Italy) 1/172 0/795 1/727 0/801 0/423
Guerini(2014)(Sardinia) 1/000 0/599 1/668 0/000 1/000
820/0191/2576/1920/1313/1dexiF
011/0895/1587/1349/0792/1modnaR
0/01 0/1 1 10 100
Favours A Favours B
Fig. 4. Forest Plot of KIR3DS1.
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Among the fourteen genes of KIR, the risk role of 2DS1 and 3DS1
were statistically significant. No significant relation was found for
other genes. Among these two genes, 2DS1 needed random effect
model because of its heterogeneity. This heterogeneity was due
to the publication bias of Torres et al. study. After applying random
effect, it did not remain not significant (P = .437) (Figs. 2 and 3).
There was no publication bias for 3DS1 and hence the fixed model
was valid (P = .028; OR = 1.31) (Figs. 4 and 5). The meta-graphs of
other genes are not shown. Family wise of KIR genes, after applying
Bonferroni’s correction no significant relation would be existed
(per family P value > 0.05).4. Discussion
4.1. Summary of evidence
The first study on this approach, dates back to 2012. Torres et al.
as the pioneers of this idea found that autism is associated with
KIR2DS1 especially in combination with its ligand HLA-C2 [20]. In
2016 they assayed haplotypes of KIR-HLA complex in patients
[15,16]. Guerini et al. (2014) found that autism was associated
with activating KIR genes both in children and their mothers. Of
course their analyses were without statistical corrections [21].
Gamliel et al. (2016) in a novel work investigated the role of mater-
nal KIR and paternal HLA-C (because uterine NK cells have maternal














Funnel Plot of Standard Error by Log odds ratio
Fig. 5. Funnel plot of KIR3DS1.
N. Pirzadroozbahani et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 159–164 163source, and half of fetal HLA-C has paternal source). In fact they
investigated the role of immunology of reproduction in autism.
They found that paternal HLA-C2 accompanied by maternal
KIR2DS1 was associated with autism in children [22]. Of course it
is not clear that whether this relation is due to fetomaternal inter-
actions (related to mothers) or due to hereditary (related to
children).4.2. Limitations
Although based on our analyses the association of KIR3DS1 was
more evident than KIR2DS1, but there is an important limitation for
KIR3DS1. The ligand of receptor 2DS1 seems to be HLA-C2, but the
ligand of protein 3DS1 is still unclear. On the other hand, finding
relations for receptor-ligand complex is more evident rather than
receptor alone. Therefore researchers were more intended to
investigate the role of KIR2DS1. Investigation of other ligands like
HLA-G can also be helpful. Guerini et al. (2017) found that
KIR2DS1 + HLA-C2 complex was more evidently associated with
autism in combination with HLA-G⁄14 bp insertion [23]. As well,
there was a controversy for KIR2DS1 that its risk relation may
not be due to a cause-effect relation, and merely it may be due
to a statistical association. Some researchers believe that receptor
2DS1 enables NK cells to fight against autoreactive T cells [18],
and because of this, KIR2DS1 is a protecting factor for multiple
sclerosis [13]. Hence it may have a positive role to inhibit patho-
logic inflammation. Another limitation of ours was that after
adjusting family comparison correction, the role of KIR3DS1 did
not remain significant.5. Conclusion
Autism spectrum disorders are accompanied by KIR3DS1 which
is an activating gene of KIR. This relation was based on our meta-
analysis, and based on previous works the association was also
existed for KIR2DS1 + HLA-C2 complex. It seems that hyper-
activity of NK cells results in inflammation in neuroimmune sys-
tem that in turn can be associated with autism. The legend of
3DS1 receptor is unknown, and suggested to be investigated. The
limitations above should be solved and then this meta-analysis
should be updated in future. It should be regarded that KIR genes
cannot be a diagnostic or prognostic method for autism. Indeed,
this work helps us to understand better the physiopathology of
autism in order to use in personalized medicine.Authors’ contribution
N Pirzadroozbahani: Search, writing paper and designing forest
plots. SAY Ahmadi: Idea, writing paper and statistical consultant. H
Hekmat: Psychiatry consultant. G Atri Roozbahani: Genetics con-
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